The Immunofixation Serum Test identifies abnormal proteins in the blood called monoclonal immunoglobulins, often linked to multiple myeloma, Waldenström macroglobulinemia, or other plasma cell disorders. Physicians use this test to detect, classify, and monitor abnormal antibody production. Results help confirm suspected conditions, assess disease progression, and guide ongoing management of disorders affecting immune system function.

The Immunofixation (IFE) Urine test detects and characterizes monoclonal proteins (free light chains/M-proteins) excreted in urine to evaluate plasma cell and lymphoproliferative disorders. It supports workup of light-chain disease, multiple myeloma, Waldenström macroglobulinemia, and amyloidosis, and helps distinguish monoclonal from polyclonal free light chains seen with glomerular leak, infection, or inflammation.

The Protein Total and Protein Electrophoresis with Immunofixation Serum Test measures total protein and separates serum proteins into fractions, with immunofixation used to detect abnormal monoclonal proteins. Doctors order this test to diagnose and monitor multiple myeloma, Waldenström’s macroglobulinemia, MGUS, and other plasma cell or immune disorders. It provides critical insight into abnormal protein production, disease activity, and treatment response.

The Kappa/Lambda Light Chains Free with Ratio and Reflex to Immunofixation Test measures free light chains in blood and calculates the kappa/lambda ratio to evaluate plasma cell disorders. Abnormal levels can indicate multiple myeloma, light chain amyloidosis, or related monoclonal gammopathies. Reflex immunofixation confirms monoclonal proteins, supporting diagnosis and monitoring of plasma cell dyscrasias.

The Kappa/Lambda Light Chains, Free with Ratio Blood Test measures free kappa and lambda light chains, proteins produced by plasma cells, and calculates their ratio. Abnormal results may indicate multiple myeloma, light chain amyloidosis, or related plasma cell disorders. Doctors use this test with serum protein electrophoresis and immunofixation to detect, diagnose, and monitor disease progression or treatment response in patients with suspected blood cancers.

The Serum Protein Electrophoresis (SPEP) Test separates proteins in blood into albumin and globulin fractions to detect abnormal patterns. Doctors order this test to evaluate multiple myeloma, Waldenström’s macroglobulinemia, amyloidosis, or chronic infections. Abnormal results may indicate monoclonal gammopathy or immune disorders. Results provide essential insight into protein balance, immune function, and blood-related cancers, guiding diagnosis and monitoring.

The Protein Total and Protein Electrophoresis Test with Scan measures total protein in blood and separates it into albumin and globulin fractions to evaluate liver, kidney, and immune function. The scan identifies abnormal protein patterns linked to multiple myeloma, Waldenström’s macroglobulinemia, or chronic inflammation. Doctors order this test for unexplained fatigue, weight loss, or anemia. Results support diagnosis, monitoring, and treatment planning.

The Protein Electrophoresis Random Urine Test analyzes protein distribution in a urine sample to detect abnormal monoclonal or polyclonal proteins. It helps evaluate multiple myeloma, kidney damage, and systemic disorders affecting protein metabolism. This test supports monitoring of urinary protein loss, renal impairment, and plasma cell disorders, offering valuable insight into overall kidney and immune health.

The Beta-2-Microglobulin (B2M) Test measures levels of B2M, a protein found on most cell surfaces and released into the blood. Elevated levels may indicate multiple myeloma, lymphoma, chronic infections, or kidney disease. Doctors order this test to evaluate cancer stage, prognosis, or kidney function. Results provide essential insight into disease progression, immune activity, and treatment monitoring for blood cancers and renal disorders.